Myozyme FDA Approval History
FDA Approved: Yes (First approved April 28, 2006)
Brand name: Myozyme
Generic name: alglucosidase alfa
Company: Genzyme Corp.
Treatment for: Pompe Disease
Myozyme is a recombinant formulation of the human enzyme acid alpha-glucosidase (GAA) indicated for use in patients with Pompe disease (GAA deficiency), a debilitating and often fatal muscle disorder.
Development timeline for Myozyme
| Date | Article |
|---|---|
| Apr 28, 2006 | Approval Myozyme Approved - Genzyme Corp. - Treatment for Pompe Disease |
| Jan 17, 2006 | Genzyme Provides Update on U.S. Marketing Application for Myozyme |
| Jul 29, 2005 | Genzyme Submits BLA for Myozyme for Treatment of Pompe Disease |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.